14 June 2004 00:01 [Source: ICB Americas]
ImClone Systems Inc. and Merck KGaA report that their cancer vaccine, IMC-BEC2, failed to meet the primary end point—survival—in a Phase III clinical trial. IMC-BEC2 mimics a ganglioside expressed on the cell membrane of most small-cell lung cancer tumors. The companies have yet to determine the future of the IMC-BEC2 development program.
Jungbunzlauer is increasing the prices of citric acid anhydrous USP/FCC and trisodium citrate dehydrate USP/FCC by approximately 7 to 10 percent to customers in the US, Canada and Mexico. The increase takes effect July 15, or as contracts allow.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.